Received Feb 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | UNK | — |
Drug prescribing error; The patient received the first dose of Shingrix in 2022 and 2nd in May 2024; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 65-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received first dose of Shingrix in 2022). In MAY-2024, the patient received the 2nd dose of Shingrix. On an unknown date, the patient did not receive the 3rd dose of Shingrix. In MAY-2024, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: The patient received the first dose of Shingrix in 2022 and 2nd in May 2024). On an unknown date, the patient experienced drug prescribing error (Verbatim: Drug prescribing error). The outcome of the drug dose administration interval too long and drug prescribing error were unknown. Additional Information: GSK Receipt Date: 03-FEB-2025 The pharmacist reported that she had a prescription for a patient for Shingrix, but it will be the patient's 3rd dose which led to drug prescribing error. The patient received the first dose of Shingrix in 2022 and 2nd in May 2024. The pharmacist thinks the physician may have forgotten the patient received the 1st dose in 2022 and that's why the 3rd dose was prescribed. The patient received 2nd dose of Shingrix longer than the recommended interval which led to lengthening of vaccination schedule.